Clinical trials: Metastasis Colorectal Cancer
Colorectal Cancer
Lapatinib Plus Trametinib in KRAS Mutant NSCLC
This is an open-label phase I/II multi-center study consisting of two parts. Part A of this study is designed to identify the recommended phase 2 dose (RP2D) of lapatinib combined with trametinib in patients with metastatic KRASm…
- Trial name
- M14LTK (NCT02230553)
- Testing
- Lapatinib, trametinib
- Where
- Netherlands
- Volunteers
- 35 people
- Sponsor
- The Netherlands Cancer Institute
Colorectal Cancer, Liver Metastases
Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients
The primary objective of this study is to assess whether the addition of Serplulimab (a PD-1 inhibitor) and Bevacizumab (an anti-angiogenesis agent) to the standard FOLFOX chemotherapy can enhance the immune microenvironment in…
- Trial name
- NCT06280495
- Testing
- Oxaliplatin, Fluorouracil, Serplulimab
- Where
- China
- Volunteers
- 156 people
- Sponsor
- Sun Yat-sen University
Colorectal Cancer
Evaluation of Efficacy and Safety of PD-1 Monoclonal Antibody in Combination With rhG-CSF, IL-2, and CapeOX in Initially Resectable Synchronous Colorectal Liver Metastases
This study attempts to employ a combination therapy using rhG-CSF, IL-2, and PD-1 inhibitors, aiming to overcome the limitations of monotherapy in immunotherapy through multi-faceted immune regulation.
- Trial name
- NCT06504901
- Testing
- Tislelizumab, Interleukin-2, Capecitabine
- Volunteers
- 30 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
RAS Wild Type mCRC
Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer
This is a single-arm, single-center, exploratory study aimed at exploring the treatment of RAS wild-type recurrent/metastatic colorectal cancer with the combination of becotatug vedotin and cetuximab as a salvage therapy
- Trial name
- NCT07490119
- Testing
- Becotatug Vedotin, Cetuximab
- Volunteers
- 31 people
- Sponsor
- Fudan University
Colorectal Cancer
Fluorouracil, Leucovorin, and Irinotecan in Treating Patients With Recurrent or Refractory Metastatic Unresectable Colorectal Cancer
RATIONALE: Drugs used in chemotherapy, such as fluorouracil, leucovorin, and irinotecan, use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00075595
- Testing
- FOLFIRI regimen, fluorouracil, irinotecan hydrochloride
- Where
- 15 sites in France
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Metastatic Colorectal Cancer, Chemotherapy Effect
Potential Predictive Biomarkers in Patients Undergoing First-line Chemotherapy for Metastatic Colorectal Cancer
Chemoresistance remains an obstacle in treating people with metastatic colorectal cancer (mCRC). Studying samples of blood and tumor tissue in the laboratory from patients with mCRC receiving chemotherapy may help doctors…
- Conditions
- Metastatic Colorectal Cancer, Chemotherapy Effect, Biomarker
- Trial name
- NCT03532711
- Testing
- fluorouracil
- Volunteers
- 264 people
- Sponsor
- Fudan University
Colorectal Cancer
SI-B001 as a Single Agent or in Combination With Chemotherapy in the Treatment of Digestive System Malignancies
This multi-center, open label Phase II clinical study is performed in patients with unresectable or metastatic malignant tumors of the digestive system (colorectal cancer, gastric cancer).
- Trial name
- NCT05039944
- Testing
- SI-B001, Irinotecan, FOLFIRI Protocol
- Where
- China
- Volunteers
- 7 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Peritoneal Carcinomatosis, Peritoneal Metastases
CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)
This is an open-label, dose-escalation, phase I trial of the safety and efficacy of anti-CEA intraperitoneal CAR-T infusions for treatment in patients with CEA-expressing adenocarcinoma peritoneal metastases or malignant ascites.
- Conditions
- Peritoneal Carcinomatosis, Peritoneal Metastases, Colorectal Cancer, Gastric Cancer
- Trial name
- NCT03682744
- Testing
- anti-CEA CAR-T cells
- Where
- 2 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Sorrento Therapeutics, Inc.
Metastatic Colorectal Cancer
Vemurafenib and Panitumumab Combination Therapy in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer
The purpose of this study is to test a new drug combination consisting of two drugs, vemurafenib (also known as ZelborafTM) and panitumumab (also known as VectibixTM).
- Trial name
- NCT01791309
- Testing
- combination panitumumab and vemurafenib
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Advanced or Metastatic Solid Tumors, Ovarian Cancer
A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors
This research study is studying a new drug, NC410, as a possible treatment for advanced or metastatic solid tumors.
- Conditions
- Advanced or Metastatic Solid Tumors, Ovarian Cancer, Gastric Cancer, Colo-rectal Cancer
- Trial name
- NCT04408599
- Testing
- NC410
- Where
- 5 sites in United States
- Volunteers
- 46 people
- Sponsor
- NextCure, Inc.
Metastatic Colorectal Cancer
Prospective Observational Study of 1st and 2nd Line Vectibix® Use in RAS-wt mCRC Pts to Evaluate Pattern of Use and ORR
The study will shed additional light on the impact of Vectibix® under the current, standard clinical conditions of mCRC treatment in Greece.
- Trial name
- VISION (NCT02322736)
- Where
- 20 sites in Greece
- Volunteers
- 218 people
- Sponsor
- Amgen
Colorectal Cancer Metastatic
Influence of BRAF and PIK3K Status on the Efficacy of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFIRI) Plus Bevacizumab or Cetuximab in Patients With RAS Wild-type Metastatic Colorectal Carcinoma and < 3 Circulating Tumor Cells (CTC)
The purpose of the study is to explore the influence of BRAF and PIK3K status on the efficacy of FOLFIRI plus Bevacizumab or Cetuximab, as first line therapy of patients with RAS wild-type metastatic colorectal carcinoma and < 3…
- Trial name
- VISNU-2 (NCT01640444)
- Testing
- FOLFIRI + bevacizumab, FOLFIRI + cetuximab
- Where
- Spain
- Volunteers
- 240 people
- Sponsor
- Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Colorectal Cancer
DJ-927 as Second-Line Therapy in Treating Patients With Progressive Locally Advanced or Metastatic Colorectal Adenocarcinoma
RATIONALE: Drugs used in chemotherapy, such as DJ-927, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00080834
- Testing
- DJ-927
- Where
- 2 sites in United States
- Sponsor
- Daiichi Sankyo
Colorectal Cancer
Treatment Outcomes of Hepatic Metastasis After FOLFOX-4 Therapy
The role of surgical resection in the subset of patients with resectable hepatic metastases converted from initially non-resectable liver metastasis was still not clearly established.
- Trial name
- NCT00610636
- Testing
- Hepatic resection
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- National Taiwan University Hospital
Colorectal Cancer Metastatic, Liver Metastases
Irinotecan Drug-eluting Bead Liver Embolisation Registry
Purpose: The purpose of this study is: to assess and define the current practice of the delivery of irinotecan loaded drug eluting beads in the treatment of liver metastases from colorectal cancer; to correlate how the delivery…
- Trial name
- DLivERDEBIRI (NCT03697044)
- Testing
- Irinotecan Drug-Eluting-Bead Trans Arterial ChemoEmbolisation
- Where
- United Kingdom
- Volunteers
- 240 people
- Sponsor
- The Christie NHS Foundation Trust
Cancer
BCX-1777 in Treating Patients With Refractory Cancer
RATIONALE: BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: Phase I trial to study the effectiveness of BCX-1777 in treating patients who have refractory cancer.
- Trial name
- NCT00073944
- Testing
- forodesine hydrochloride
- Where
- United States
- Sponsor
- BioCryst Pharmaceuticals
Colorectal Cancer
Phase Ib/II Study of QL1706 + Fruquintinib + SCRT vs. Standard Third-Line Therapy in Unresectable Liver-Metastatic pMMR/MSS Colorectal Cancer: Safety, Tolerability, and Efficacy.
This study is designed to evaluate the safety, tolerability, and efficacy of Epalolitovoreli Monoclonal Antibody (QL1706) combined with Fruquintinib and Short-Course Radiotherapy (SCRT), compared with standard third-line therapy…
- Trial name
- NCT07353268
- Testing
- QL1706 + Fruquintinib + Short-Course Ablative Radiotherapy (SCART), Standard Third-Line Therapy
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Tao Zhang
C04.588.274.476.411.307
XELOX III. Xeloda in Combination With Eloxatin for Patients With Advanced or Metastatic Colorectal Cancer
XELOX (Capecitabine and Oxaliplatin) is an effective and convenient regimen for patients with metastatic colorectal cancer. Chronomodulated therapy may reduce toxicity.
- Trial name
- NCT00212615
- Testing
- Oxaliplatin (Eloxatin), Capecitabine (Xeloda)
- Where
- 8 sites in Denmark, Sweden
- Volunteers
- 116 people
- Sponsor
- Odense University Hospital
Metastatic Colorectal Cancer (CRC)
A Single-arm, Multicenter Clinical Study of Fruquintinib Combined With Serplulimab and Chemotherapy as First-line Treatment for Patients With RAS/BRAF-mutated Advanced Colorectal Cance
This study is a prospective, single-arm, multicenter exploratory clinical study aimed at evaluating the efficacy and safety of Fruquintinib combined With Serplulimab and chemotherapy as first-line treatment for RAS/BRAF-mutated…
- Trial name
- NCT07622550
- Testing
- Serplulimab+Fruquintinib+XELOX
- Where
- 16 sites in China
- Volunteers
- 80 people
- Sponsor
- Jiangsu Cancer Institute & Hospital
Colorectal Cancer Metastatic
Galunisertib and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer
Part I of this study is designed to identify the recommended phase 2 dose (RP2D) of the combination regimen of galunisertib/capecitabine as second line treatment in patients with 5-FU or capecitabine resistant CRC.
- Trial name
- EORTC1615 (NCT03470350)
- Testing
- Galunisertib
- Where
- Netherlands
- Sponsor
- The Netherlands Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.